A Phase 3 interventional study of CKD-843 dose#1 and CKD-843 dose#2 in Androgenetic Alopecia, sponsored by Chong Kun Dang Pharmaceutical. Recruiting at 1 site in South Korea. Open to male participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Alopecia with a site in Korea, Republic of — 5 open to participants now, 5 under way, 3 of them phase 3. Alopecia · Korea, Republic of.
Among the 22 studies in Alopecia with a site in Korea, Republic of, this one is the 5th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 3, and was the 19th registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →5 of the 22 studies in Alopecia with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Epibiotech · Sites in Korea, Republic of
Ages 19+
Pfizer · Sites in Korea, Republic of, United States, Canada and 8 more countries
Ages 12+
Eli Lilly and Company · Sites in Korea, Republic of, United States, Argentina and 9 more countries
Ages 6–17
Moogene Medi Co., Ltd · Sites in Korea, Republic of
Ages 19–55 · Men only · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 50 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 7
First in 2010; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 288 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 80 across the 21 interventional studies, 712 across the 1 observational. Of the 17 that completed or were terminated, 3 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 22 have an industry lead sponsor. The 10 most frequent:
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
Chong Kun Dang Pharmaceutical has 4 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
1 of the studies in Alopecia with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06916793Phase 3Chong Kun Dang PharmaceuticalA Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Alopecia with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
The participants were randomly assigned to one of the following groups: CKD-843 dose #1, CKD-843 dose #2, placebo, or Dutasteride group. They received the assigned medication, placebo for blinding, or the reference drug over a 12-month period.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CKD-843 dose#1 + Placebo of Dutasteride Capsule
Drug: CKD-843 dose#1 · Drug: Placebo of Dutasteride Capsule
CKD-843 dose#2 + Placebo of Dutasteride Capsule
Drug: CKD-843 dose#2 · Drug: Placebo of Dutasteride Capsule
Placebo of CKD-843 dose + Placebo of Dutasteride Capsule
Drug: Placebo of CKD-843 dose · Drug: Placebo of Dutasteride Capsule
Placebo of CKD-843 dose + Dutasteride Capsules
Drug: Placebo of CKD-843 dose · Drug: Dutasteride Capsules
IM injection every 3 months for 12 months
IM injection every 3 months for 12 months
IM injection every 3 months for 12 months
oral, once daily, 12 months
oral, once daily, 12 months
Total number of hair Changes
from Baseline at Week24 of total number of hair changes
Time frame: Baseline, Week 24
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Sep 2027, 29 months after the start.
Of 28 phase 3 interventional studies under Alopecia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 29 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CKD-843
Chong Kun Dang Pharmaceutical →